Icon (Australia)

Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time

Mikel Byrne, Ben Archibald‐Heeren, Yunfei Hu et al. · Journal of Applied Clinical Medical Physics · 2021 · 217 citations · Full text

Medicine, Oncology, Biomedical Imaging +16

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 172 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 163 citations · Full text

Medicine, Oncology, Pharmacology +10

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

Youn H. Kim, H. Miles Prince, Sean Whittaker et al. · European Journal of Cancer · 2021 · 58 citations · Full text

Medicine, Dermatology, Oncology +13

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Karim Fizazi, Margitta Retz, Daniel P. Petrylak et al. · Journal for ImmunoTherapy of Cancer · 2022 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17